About tislelizumab
PD-1 immune checkpoint inhibitor
Used for
- Treats certain cancers, including esophageal, gastric, and lung cancers, depending on approval and treatment setting.
Usual adult dose
Usually 200 mg by intravenous infusion every 3 weeks; some cancer regimens use 400 mg every 6 weeks.
Common side effects
- Tiredness
- Rash or itching
- Diarrhea
- Infusion reactions
Important warnings
- Can cause immune system attacks on healthy organs, including lungs, bowel, liver, kidneys, and hormone glands.
- Serious or fatal immune-related reactions can occur during treatment or after it ends.
- Infusion reactions and severe allergic reactions are possible.
- Treatment requires monitoring by a cancer specialist.
Pregnancy
May harm an unborn baby. Pregnancy should be avoided during treatment and for at least 4 months afterward.
Breastfeeding
Do not breastfeed during treatment and for at least 4 months after the last dose.
Interactions
- Other medicines that suppress the immune system may affect treatment or increase risks.
AI-generated from general medical knowledge, not from this product's official leaflet. It may be incomplete or out of date. Not medical advice — ask a pharmacist or doctor before making any decision.